Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1921 to 1935 of 8817 results

  1. Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]

    In development Reference number: GID-TA11334 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Sutimlimab for treating haemolytic anaemia in people with cold agglutinin disease [ID6673]

    Awaiting development Reference number: GID-TA11892 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Loncastuximab Tesirine + Rituximab for Diffuse large B-cell lymphoma [ID6686]

    Awaiting development Reference number: GID-TA11904 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]

    In development Reference number: GID-TA11818 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]

    In development Reference number: GID-TA11859 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Endoscopic submucosal dissection knives for the resection of complex colorectal polyps with suspected submucosal invasion

    In development Reference number: GID-HTE10072 Expected publication date:  19 November 2026

    Health technology evaluations
    In development

  7. MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]

    In development Reference number: GID-TA10573 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Levodopa/carbidopa (ND0612) for Parkinson's Disease [ID6727]

    Awaiting development Reference number: GID-TA11954 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Sepiapterin for treating hyperphenylalaninaemia in phenylketonuria in people of any age [ID6750]

    Awaiting development Reference number: GID-TA11982 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]

    In development Reference number: GID-TA11468 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver

    In development Reference number: GID-IPG10448 Expected publication date:  15 October 2026

    Interventional procedures guidance
    In development

  12. Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579]

    In development Reference number: GID-TA11780 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Elranatamab for treating relapsed or refractory multiple myeloma after 2 treatments [ID6464]

    Awaiting development Reference number: GID-TA11661 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]

    In development Reference number: GID-TA11116 Expected publication date:  11 November 2026

    Technology appraisal guidance
    In development

  15. Nirogacestat for treating desmoid tumours [ID6453]

    In development Reference number: GID-TA11559 Expected publication date:  10 June 2026

    Technology appraisal guidance
    In development